Product Data Sheet

(R)-BDP9066

Cat. No.: HY-111424A CAS No.: 2284549-25-1 Molecular Formula: $C_{20}H_{24}N_{6}$ Molecular Weight: 348.44 Others Target:

Storage: Powder -20°C 3 years

Others

2 years

-80°C In solvent 6 months

> -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

Pathway:

DMSO: 20 mg/mL (57.40 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.8699 mL	14.3497 mL	28.6993 mL
	5 mM	0.5740 mL	2.8699 mL	5.7399 mL
	10 mM	0.2870 mL	1.4350 mL	2.8699 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2 mg/mL (5.74 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2 mg/mL (5.74 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

(R)-BDP9066 is a potent inhibitor of myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK). (R)-BDP9066 blocks cancer cell invasion. (R)-BDP9066 has the potential for the research of proliferative diseases, such as cancer.

REFERENCES

[1]. Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer. Patent WO2019034890A1.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com